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Clinical Outcome In Patients With Low Left Ventricular Function Undergoing
Transcatheter Aortic Valve Replacement
Israel Barbash, Danny Dvir, Saar Minha, Itsik Ben Dor, Salem Badr, Joshua P Loh,
Lakshmana Pendyala, Hironori Kitabata, Rebecca Torguson, Petros Okubagzi,
William Suddath, Lowell Satler, Kenneth Kent, Augusto Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC
Background: Left ventricular ejection function (LVEF) recovers in the majority of
patients with aortic stenosis (AS) who undergo aortic valve replacement. However the
outcomes of patients with low EF who undergo transcatheter aortic valve replacement
(TAVR) are not well defined.
Methods: Retrospective analysis of AS patients with normal versus mildly or severely
impaired left ventricular function who underwent TAVR was done. Patients were divided
according to baseline LVEF as normal (LVEF  0.50), mild-moderate (0.40  EF 
0.50) and severe (LVEF0.40) dysfunction.
Results: A total of 242 patients were included in the present analysis. 163 patients (67%)
had normal LVEF, 43 had mild-moderate (18%) and 36 (15%) had severe LV
dysfunction. Baseline demographics were generally comparable apart from higher rates of
women and STS score among patients with LV dysfunction (Table). There was no
difference in access approach with 72% of the patient having transfemoral access. No
significant difference in the in hospital and long term outcome were found (Table).
Conclusions: Patients with severe AS and impaired LV function who undergo TAVR
may gain similar benefit from the procedure as patients with normal LV function.
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Background: Edwards Sapien transcatheter valve is FDA approved for commercial use
in non-operable patients with severe symptomatic aortic stenosis (AS) via the transfemoral
approach.
Objective: To assess the clinical profile and in-hospital complications in patients treated
with commercial valve compared to PARTNER cohort B.
Methods: Study included all consecutive patients treated with commercial Sapien valve
at our institution. Baseline characteristics, clinical presentation and in-hospital complica-
tions were analyzed. Among all trasfemoral cases 37 commercial valve patients were
compared to 54 patients in cohort B.
Results: All clinical variables are similar between the groups including STS score (9.44
vs. 10.75, p0.24) except commercial patients had more insulin dependent diabetes
mellitus and dialysis dependent renal failure. In majority of the patients in the commercial
arm the procedure was done with conscious sedation (81% vs. 56%, p0.02). The use of
planned surgical cut down for vascular access is also rare (4% vs. 85%, P0.001) in
commercial group. 100% procedural success in both the groups with valve deployment.
There is trend for lower vascular and bleeding complications with less blood transfusion
rates (27% vs. 59%, p0.007) in the commercial patients. The in-hospital mortality and
stroke rates are similar between the groups.
Conclusions: The initial commercial use of the Edwards Sapien valve for inoperable
patients reported to have similar success rates in valve deployment, in-hospital mortality
and stroke rate when compared to PARTNER cohort B patients. The refinement in the
procedure with more conscious sedation, experience of the operators and careful vascular
planning with more percutaneous access in the commercial group lead to the trends for
lower vascular complications and the requirement of blood transfusions.
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Clinical and procedural characteristics and in-hospital complications
Variable
Commercial
Valve
(n37)
Cohort B
(n54) p value
Mean age (yearsSD) 838 837 0.87
Dialysis 11% 0 0.04
Conscious sedation 81% 56% 0.02
Planned surgical cut down 4% 85% 0.001
VARC major vascular complication 5% 22% 0.14
VARC life threatening bleed 9% 13% 0.69
Transfusion rates 27% 59% 0.007
Stroke 8% 11% 1
In-hospital mortality 2 0 0.1
Closure of Valve Leaks
CRT-139
A Single Center Experience Of Percutaneous Transcatheter Closures Of
Paravalvular Leaks
Vasilis Babaliaros,1 Murad Abdelsalam,2 Sameer Gafoor,1 James stewart,1
Vinod Thourani,1 Peter Block1
1Emory University, Atlanta, GA; 2Pinnacle Health Hospitals, Harrisburg, PA
Background: Percutaneous transcatheter closure of Paravalvular leaks is a new alternative
approach to re-do surgery, which is associated with considerable mortality and morbidity.
We aim to evaluate feasibility and short term results with this novel closure technique.
Methods: Between May 2007 and September 2011. 16 symptomatic patients (seven
males, nine females; mean age 59.1  17.9 years) with heart failure (n9 ), hemolytic
anemia (n2) or both (n5) underwent percutaneous PVL closure at our center. Most
patients were high risk for open surgical repair (STS score 7.64  8.02) with average
number of sternotomies equal to 2.3 (range 0-4). Both left and right sided valves were
intervened upon including Mitral valves (n10), Aortic valves (n5), one of which was
a trans-catheter placed Sapien Valve, Pulmonic valves ( n1). The procedure was done
under echocardiographic and fluoroscopic guidance using the Amplatzer Septal Occluder,
Duct Occluder or Vascular Plug II.
Results: Successful percutaneous repair was achieved in 12 out of 16 patients (75%).
Failure to cross the leak with either the wire or the catheter occurred in two patients. In
the other two patients, device was deployed with residual moderate regurgitation. There
were no procedural or unexplained death, but there were two post procedural deaths, one
patient had severe septic shock and the other had cardiogenic shock prior to intervention.
No emergency surgery or device embolization occurred .One patient had an ischemic
stroke in the fifth post-operative day. One patient with multiple defects and a failed
attempt required an elective surgical repair to seal the leak.
Conclusions: Percutaneous transcatheter closure of paravalvular leaks is feasible but
appears to be technically demanding procedure with acceptable success rate especially in
poor surgical candidate. Further experience is warranted to evaluate long term morbidity
and mortality.
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Percutaneous Mitral Valve Repair with MitraClip Restores Exercise Capacity in
Patients with Symptomatic Severe Functional Mitral Regurgitation who are Not
Surgical Candidates
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1Tan Tock Seng Hospital, Singapore, Singapore 2National University Heart Centre,
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Introduction: Functional Mitral Regurgitation (FMR) may cause Heart Failure (HF).
Cardiac surgery for open correction of FMR in patients with severely impaired left
ventricular ejection fraction (LVEF) or prior cardiac surgery entails higher risk. The
EVEREST II Trial in patients who were surgical candidates for mitral valve repair
showed outcomes of percutaneous repair using the MitraClip were comparable with
surgery.
Hypothesis: We hypothesized that MitraClip is safe and effective in patients with severe
FMR and HF who are not surgical candidates.
Methods: We identified 4 patients with significant FMR and limited exercise capacity
due to HF. Significant ischemia was excluded with functional imaging. Surgical risk was
deemed prohibitive. Mitral valve anatomy was assessed by transthoracic (TTE) and
transesophageal echocardiography.
Patients: One patient was female, 2 had AF, 3 had prior remote coronary artery bypass
graft surgery, and the 4th had non-ischemic cardiomyopathy. Age was 59  11 years,
BSA 1.7  0.1 m2, GFR 57.5  46.9mls/min, Hemoglobin 11.2  1.4g/dL. NYHA
2.75  0.5, LVEF 30  17%, MR grade 3.75  0.5, Six-Minute Walk Distance
(6MWD) 208  132m, and Euroscore risk for cardiac surgery 32.9  26.9%.
Results: All patients underwent successful MitraClip procedures without complication.
Three patients used 1 clip, while 1 patient required 2 clips. MR grade was reduced to
1.25  0.5 and patients were discharged 2.25  0.96 days post MitraClip. Follow-up
TTEs show durability of MR reduction (Fig 1.). 6MWD improved to 423  92m
(p0.037). Two patients have resumed working, and all can participate in normal
activities of daily living. They remain on standard pharmacotherapy for heart failure.
Conclusion: In conclusion, MitraClip is safe and effective in restoring exercise capacity
in selected patients with severe FMR and HF who are not surgical candidates.
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